A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bishop MJ. The molecular genetics of cancer. Leukemia 1988;2:199–208.
Brison O. Gene amplification and tumor progression. Biochim Biophys Acta 1993;25:1155(1):25-41.
Akiyama T, Sudo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644–6.
Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics 1989;4(3):362–6.
Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. Science 1985;230:1132–9.
DiAugustine RP, Richards RG, Sebastian J. EGF-related peptides and their receptors in mammary gland development. J Mammary Gland Biol Neoplasia 1997;2:109–17.
Normanno N, Ciardiello F. EGF-related peptides in the pathophysiology of the mammary gland. J Mammary Gland Biol Neoplasia 1997;2:143–51.
Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987;235:177–235.
Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER2/neu protooncogene in human breast and ovarian cancer. Science 1989;244:707–12.
Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of cerbB-2 expression in breast cancer. J Clin Oncol 1992;7:1049–56.
Andrulis IL, Bull SB, Blackstein ME, et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 1998; 16:1340–9.
Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastasic breast cancer that has progressed after chemotherapy for metastasic disease. J Clin Oncol 1999;17:2639–48.
Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737–44.
Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancerxenografts. Cancer Res 1998;58:2825–31.
Pietras RJ, Pegram MD, Finn RS, Maneval DA, Siamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998;17:2235–49.
Slamon DJ, Godolphin W, Jones LA, et al. Studies of HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;12:707–12.
Press MF, Hung G, Godolphin W, et al. Sensivity of HER2/neu antibodies in archival Tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Research 1994;54:2771–7.
Pauletti G, Godolphin W, Press MF, et al. Detection and quantification of HER2/neu gene amplification in human breast cancer archival material using fluorescencein situ hybridization. Oncogene 1996;13:63–72.
Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescencein situ hybridization. Proc Natl Acad Sci USA 1992;89(12): 5321–5.
Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescencein situ hybridization and immunohistochemistry for the evaluation of HER2/neu in breast cancer. J Clin Oncol 1999;17:1974–82.
Lebeau A, Deimling D, Kaltz C, et al. HER2/neu analysis in archival tissue samples of human breast cancer: Comparision of immunohistochemistry and fluorescencein situ hybridization. J Clin Oncol 2001;19:354–63.
Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and placlitaxel therapy for metastasic breast cancer analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587–95.
Naber SP, Tsutsumi Y, Yin S, et al. Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. Am J Clin Pathol 1990; 94:125–36.
Vogel CL, Cobleight MA, Tripathy D, et al. First-line herceptin® monotherapy in metastasic breast cancer. Oncology 2001;S2:37–42.
Baselga J. Herceptin® alone or in combination with chemoterapy in the treatment of HER2 positive metastasic breast cancer: pivotal trials. Oncology 2001;S2:4–21.